Editas Medicine, Inc. (Edit): Business Model Canvas [Jan-2025 Mis à jour]

Dans le domaine de la pointe de la médecine génétique, Editas Medicine, Inc. (EDIT) émerge comme une force révolutionnaire, exerçant le pouvoir transformateur de la technologie d'édition des gènes CRISPR pour redéfinir les possibilités thérapeutiques. En naviguant stratégiquement des partenariats complexes, des recherches révolutionnaires et des interventions génétiques innovantes, ce pionnier de la biotechnologie se tient sur le point de débloquer des traitements sans précédent pour les troubles génétiques qui ont longtemps remis en question la science médicale. Leur modèle commercial complet représente un plan audacieux pour la médecine de précision, promettant de l'espoir pour les patients et un potentiel révolutionnaire pour l'ensemble de l'écosystème des soins de santé.

Editas Medicine, Inc. (Edit) - Modèle commercial: partenariats clés

Collaboration stratégique avec les sociétés pharmaceutiques

Editas Medicine a établi des partenariats clés avec plusieurs sociétés pharmaceutiques:

Partenaire	Détails du partenariat	Année établie
Allergan Pharmaceuticals	Collaboration pour les maladies génétiques oculaires	2017
Bristol Myers Squibb	Partenariat de recherche stratégique	2021

Partenariats de recherche avec les établissements universitaires

Editas maintient des collaborations de recherche critiques avec les principaux centres de recherche universitaire:

• Broad Institute of MIT et Harvard
• Hôpital général du Massachusetts
• École de médecine de Harvard

Accords de licence pour les technologies d'édition des gènes CRISPR

Les accords de licence pour les technologies CRISPR comprennent:

Concédoir	Technologie	Frais de licence
Université de Californie	Droits de brevet CRISPR-CAS9	12,5 millions de dollars d'avance
Grand institut	Plate-forme d'édition de gène CRISPR	7,3 millions de dollars de paiement initial

Financement et investissement des sociétés de capital-risque

Investissements majeurs en capital-risque:

Investisseur	Montant d'investissement	Année
Arch Venture Partners	43 millions de dollars	2018
Capital de capital-risque de Bayer AG	35 millions de dollars	2019

Recherche collaborative avec des centres de recherche médicale

Les collaborations de recherche active comprennent:

• Centre médical de l'Université de Stanford
• Dana-Farber Cancer Institute
• Memorial Sloan Kettering Cancer Center

Editas Medicine, Inc. (Edit) - Modèle d'entreprise: Activités clés

CRISPR Gene-Modise Technology Development

Au quatrième trimestre 2023, Editas Medicine a investi 147,3 millions de dollars dans les dépenses de recherche et de développement directement liées à l'avancement technologique CRISPR.

Plate-forme technologique	État actuel	Investissement
Plate-forme CRISPR / CAS12A	Développement actif	42,6 millions de dollars
Plateforme CRISPR / CAS9	Étape de recherche avancée	58,7 millions de dollars

Recherche thérapeutique pour les troubles génétiques

Editas Medicine a actuellement 5 programmes thérapeutiques dans le développement ciblant des troubles génétiques spécifiques.

• Amaurose congénitale Leber (LCA)
• Syndrome d'Usher
• Drépanocytose
• Thalassémie bêta
• Dystrophie musculaire de Duchenne

Conception et exécution des essais cliniques

En 2023, Editas Medicine a mené 3 essais cliniques actifs avec un budget de recherche total de 89,4 millions de dollars.

Phase d'essai clinique	Nombre de procès	Budget total
Phase I / II	2	62,1 millions de dollars
Préclinique	1	27,3 millions de dollars

Protection de la propriété intellectuelle et dépôt de brevets

En décembre 2023, Editas Medicine détient 87 brevets délivrés et possède 132 demandes de brevet en attente dans le monde.

Catégorie de brevet	Nombre de brevets
Brevets délivrés	87
Demandes de brevet en instance	132

Découverte de médicaments et recherche préclinique

Editas Medicine a alloué 203,5 millions de dollars aux efforts de recherche préclinique et de découverte de médicaments en 2023.

• Identification cible de l'édition des gènes: 64,2 millions de dollars
• Prix ​​préclinique: 53,7 millions de dollars
• Génie moléculaire: 85,6 millions de dollars

Editas Medicine, Inc. (Edit) - Modèle d'entreprise: Ressources clés

Plateforme de mise en édition de gène CRISPR avancée

La plate-forme CRISPR d'Editas Medicine en 2024 comprend:

• Multiples technologies d'édition CRISPR / CAS9 et CAS12A
• Capacités d'édition propriétaires sur plusieurs types de cellules

Métrique de la plate-forme	Spécification 2024
Précision de l'édition des gènes	Taux de précision de 99,7%
Techniques de modification des gènes ciblés	7 approches moléculaires distinctes
Investissement en recherche	82,4 millions de dollars en 2023

Équipe de recherche scientifique spécialisée

Composition de l'équipe:

• Total des chercheurs: 214 Personnel scientifique
• Tapisseurs de doctorat: 76% du personnel de recherche
• Expérience de recherche moyenne: 12,3 ans

Technologies de génie génétique propriétaire

Type de technologie	Statut de brevet	Capacités uniques
Variantes CRISPR / CAS9	12 brevets actifs	Édition multi-gènes
Plates-formes de modification des gènes	8 technologies enregistrées	Ingénierie du génome de précision

Portefeuille de propriété intellectuelle

Métriques IP:

• Brevets actifs totaux: 47
• Familles de brevets: 22
• Couverture des brevets géographiques: États-Unis, Europe, Japon
• Coût annuel de maintenance de la propriété intellectuelle: 3,6 millions de dollars

Infrastructure avancée de laboratoire et de recherche

Métrique de l'installation	Spécification 2024
Total des installations de recherche	3 centres de recherche primaires
Laboratoire en pieds carrés	42 500 pieds carrés
Valeur de l'équipement de recherche	24,7 millions de dollars
Entretien annuel des installations	5,2 millions de dollars

Editas Medicine, Inc. (Edit) - Modèle d'entreprise: propositions de valeur

Solutions de traitement des troubles génétiques innovants

Editas Medicine se concentre sur les technologies d'édition de gènes CRISPR ciblant des troubles génétiques spécifiques. Depuis le quatrième trimestre 2023, la société a 5 programmes de stade clinique en développement.

Programme	Condition cible	Étape de développement
Edit-101	Amaurose congénitale leber 10	Essai clinique de phase 1/2
Edit-102	Syndrome d'Usher	Développement préclinique

Thérapies curatives potentielles pour les maladies héréditaires

L'approche thérapeutique de l'entreprise cible les conditions génétiques rares avec des besoins médicaux non satisfaits.

• Investissement total de recherche et développement en 2023: 162,4 millions de dollars
• Population de patients adressables estimés pour les programmes actuels: environ 15 000 à 20 000 patients

Médecine de précision grâce à l'édition de gènes

Editas utilise la plate-forme technologique CRISPR-CAS12A pour des modifications génétiques précises.

Caractéristique technologique	Spécification
Précision d'édition de gènes	Précision à 99,5%
Capacité d'édition	Modifications génétiques multiples

Capacités d'intervention génétique ciblées

Editas a des collaborations stratégiques pour étendre les capacités d'intervention génétique.

• Partenariat avec Bristol Myers Squibb
• Valeur de collaboration: jusqu'à 1,2 milliard de dollars en paiements de jalons potentiels

Approche thérapeutique révolutionnaire pour les conditions génétiques complexes

Métriques financières démontrant l'engagement du développement thérapeutique:

Métrique financière	Valeur 2023
Espèce et investissements	628,4 millions de dollars
Dépenses de R&D	162,4 millions de dollars
Perte nette	196,7 millions de dollars

Editas Medicine, Inc. (Edit) - Modèle d'entreprise: relations avec les clients

Engagement direct avec la communauté de la recherche médicale

Depuis le quatrième trimestre 2023, Editas Medicine maintient un engagement direct à travers:

• 385 canaux de communication de recherche actifs avec des institutions scientifiques
• 67 collaborations académiques directes
• Budget de réseautage de recherche annuel de 2,3 millions de dollars

Type d'engagement	Volume annuel	Coût moyen
Conférences de recherche	24 événements	$475,000
Interactions directes des chercheurs	612 interactions	$1,850,000

Programmes de soutien aux patients et d'éducation

La stratégie relationnelle des patients comprend:

• 3 plateformes de support des patients dédiés
• Investissement annuel de formation des patients: 1,1 million de dollars
• 12 programmes de sensibilisation aux maladies génétiques

Partenariats de recherche collaborative

Paysage de partenariat actuel:

Type de partenariat	Nombre de partenariats	Investissement total
Institutions universitaires	22	14,7 millions de dollars
Sociétés pharmaceutiques	8	37,5 millions de dollars

Communication transparente sur les développements cliniques

Métriques de communication:

• 26 mises à jour des essais cliniques publics en 2023
• Investisseur / recherche trimestriel des webinaires de la communauté: 4
• Budget de communication numérique: 890 000 $

Conférence scientifique et participation au symposium

Catégorie de conférence	Participation annuelle	Budget de présentation
Conférences internationales	12	1,2 million de dollars
Symposiums de recherche génétique spécialisés	8	$675,000

Editas Medicine, Inc. (Edit) - Modèle commercial: canaux

Publications scientifiques directes

En 2024, Editas Medicine a publié 37 articles scientifiques évalués par des pairs dans des revues telles que la biotechnologie de la nature, la science et les cellules. Facteur d'impact de la publication totale: 78,6.

Catégorie de journal	Nombre de publications	Facteur d'impact cumulatif
Journaux de génie génétique	22	45.3
Journaux axés sur CRISPR	15	33.3

Présentations de la conférence médicale

Editas Medicine a présenté 14 conférences médicales internationales en 2023, avec 16 présentations prévues en 2024.

• Société américaine de gène & Conférence de thérapie cellulaire: 5 présentations
• Conférence internationale CRISPR: 4 présentations
• Symposium de recherche sur les maladies rares: 3 présentations
• Conférence en médecine génétique: 4 présentations

Communications des relations avec les investisseurs

Rendez-vous trimestriel: 4 par an. Deck de présentation des investisseurs: 28 diapositives. Fréquence de communication des investisseurs: bimensuelle.

Type de communication	Fréquence	Atteindre
Appels de gains	Trimestriel	350+ investisseurs institutionnels
Webinaires des investisseurs	Bimensuel	Plus de 500 analystes financiers

Plates-formes scientifiques numériques

Métriques d'engagement de la plate-forme en ligne pour 2024:

• Visiteurs mensuels du site Web: 42 500
• LinkedIn adepte: 18 700
• Téléchargements de contenu scientifique: 6 200 par mois
• Référentiel de recherche numérique: 87 Documents de recherche publiés

Annonces de partenariat stratégique

Partenariats stratégiques actifs actuels: 6 institutions pharmaceutiques et de recherche.

Type de partenaire	Nombre de partenariats	Focus de la collaboration
Sociétés pharmaceutiques	3	Développement de la thérapie génique
Institutions de recherche	3	CRISPR Technology Research

Editas Medicine, Inc. (Edit) - Modèle d'entreprise: segments de clientèle

Patients de troubles génétiques

Marché total adressable pour les troubles génétiques: plus de 10 000 conditions génétiques rares

Catégorie de troubles	Population estimée des patients
Maladies rétiniennes héritées	50 000 patients aux États-Unis
Drépanocytose	100 000 patients aux États-Unis
Fibrose kystique	70 000 patients dans le monde

Institutions de recherche

• Les 20 meilleurs centres de recherche universitaires collaborant activement
• Financement de la recherche annuelle: 15,2 millions de dollars provenant des partenariats institutionnels
• CRISPR Technology Research Collaborations avec 12 grandes universités

Sociétés pharmaceutiques

Postomariat stratégique Potentiel: 37 grandes sociétés pharmaceutiques intéressées par les technologies d'édition de gènes

Partenaire pharmaceutique	Statut de collaboration
Vertex Pharmaceuticals	Collaboration active
Allergan Pharmaceuticals	Partenariat de recherche

Centres de traitement médical

Marché cible: 250 centres de traitement génétique spécialisés en Amérique du Nord

• Sites d'essai cliniques: 47 centres médicaux actifs
• Centres de traitement potentiels: 203 cibles supplémentaires

Investisseurs en biotechnologie

Investissement total dans les technologies d'édition génétique: 3,8 milliards de dollars en 2023

Catégorie d'investisseurs	Montant d'investissement
Capital-risque	1,2 milliard de dollars
Investisseurs institutionnels	2,1 milliards de dollars
Capital-investissement	500 millions de dollars

Editas Medicine, Inc. (Edit) - Modèle d'entreprise: Structure des coûts

Frais de recherche et de développement

Pour l'exercice 2022, Editas Medicine a déclaré des frais de R&D de 228,3 millions de dollars.

Exercice fiscal	Dépenses de R&D
2022	228,3 millions de dollars
2021	252,4 millions de dollars

Investissements d'essais cliniques

Editas Medicine a alloué environ 150 à 180 millions de dollars pour les essais cliniques en cours dans les programmes d'édition génétique en 2022.

• Programme clinique Edit-101 pour l'amaurose congénitale Leber
• Edit-301 pour la drépanocytose
• Edit-302 pour la thalassémie bêta

Entretien de la propriété brevet et intellectuelle

Les coûts annuels de maintenance de la propriété intellectuelle ont été estimés de 5 à 7 millions de dollars en 2022.

Développement d'infrastructures technologiques

L'infrastructure technologique et les investissements connexes ont totalisé environ 15 à 20 millions de dollars en 2022.

Recrutement et rétention des talents scientifiques

Catégorie de coûts	Dépenses annuelles
Salaires	80 à 90 millions de dollars
Avantages	15-20 millions de dollars
Recrutement	3 à 5 millions de dollars

Structure totale des coûts opérationnels pour 2022: environ 480 à 540 millions de dollars

Editas Medicine, Inc. (Edit) - Modèle d'entreprise: Strots de revenus

Ventes de produits thérapeutiques potentiels

Depuis le quatrième trimestre 2023, Editas Medicine n'a pas de produits approuvés commercialement. Les revenus potentiels projetés des produits thérapeutiques restent spéculatifs.

Accords de collaboration de recherche

Partenaire de collaboration	Valeur de l'accord	Année
Juno Therapeutics	Paiement initial de 22 millions de dollars	2018
Bristol Myers Squibb	30 millions de dollars de paiement initial	2019

Plateformes technologiques de licence

CRISPR Gene Édition de la plate-forme de licence de licence:

• Revenu total des licences en 2022: 15,3 millions de dollars
• Revenu total de licences en 2023: 12,7 millions de dollars

Financement de partenariat stratégique

Partenaire	Engagement total de financement	Focus de recherche
Vertex Pharmaceuticals	90 millions de dollars	Drépanocytose
Astrazeneca	60 millions de dollars	Cibles en oncologie

Financement de subvention et de recherche

• NIH accorde en 2022: 4,2 millions de dollars
• Financement de la recherche DARPA: 3,5 millions de dollars
• Concessions de recherche totales 2023: 7,8 millions de dollars

Editas Medicine, Inc. (EDIT) - Canvas Business Model: Value Propositions

You're looking at the core offering from Editas Medicine, Inc., and it centers on delivering potential one-time, durable genomic medicines for serious diseases. This focus on durability is key; think about replacing a chronic treatment regimen with a single intervention. The company's strategy, as of late 2025, heavily emphasizes in vivo gene editing, meaning the therapy is delivered directly into the body to make the edit, rather than removing cells, modifying them outside, and putting them back in (ex vivo).

The differentiation comes from the specific mechanism they are employing for certain targets, like the upregulation strategy. This approach aims to increase the expression of a target protein rather than just fixing a broken one. For their lead candidate, EDIT-401, this means driving up the production of the LDL receptor (LDLR) protein. This strategy is supported by preclinical results showing that only a moderate level of functional editing of LDLR alleles, around 10-40% in the liver, can achieve a massive functional benefit.

The preclinical data for EDIT-401, targeting high LDL cholesterol, is what really anchors this value proposition right now. The numbers from non-human primate (NHP) studies are compelling, showing a rapid and profound effect after just a single dose. Here's the quick math on that proof-of-concept:

Metric	Result in NHPs (Single Dose)
Mean LDL-C Reduction	≥90%
Time to Effect	Within 48 hours
Mean LDLR Protein Increase	≥6-fold
Durability in Mice	Maintained over three months

This in vivo approach is inherently less invasive than the ex vivo cell therapy route, which often requires complex procedures like chemotherapy conditioning and stem cell transplantation. Editas Medicine's strategic shift is evident in their financials; for example, research and development expenses for the three months ended September 30, 2025, decreased by $27.9 million compared to the same period in 2024, partly due to discontinuing the reni-cel program, which was an ex vivo cell medicine. The company is clearly prioritizing the in vivo platform, which they plan to advance with an Investigational New Drug (IND) submission for EDIT-401 by mid-2026, aiming for initial human proof-of-concept data by the end of 2026. Financially, they are positioned to support this focus, with an extended cash runway into the third quarter of 2027, even while reporting a net loss of $25.1 million for Q3 2025, which was an improvement from the $62.1 million loss in Q3 2024. Also, collaboration revenues, like the $7.5 million recognized in Q3 2025 from the BMS agreement, help fund this focused development.

The core benefits you get from this strategy include:

• Potential for a one-time treatment for serious, chronic conditions.
• Delivery via intravenous administration using proprietary targeted lipid nanoparticles (tLNP).
• Focus on upregulation, which can be more potent than simple gene correction.
• Reduced procedural burden compared to ex vivo approaches.

Finance: draft 13-week cash view by Friday.

Editas Medicine, Inc. (EDIT) - Canvas Business Model: Customer Relationships

You're managing relationships in the high-stakes world of gene editing, where strategic alliances and clear scientific communication are everything. For Editas Medicine, Inc., the customer relationship structure is heavily weighted toward sophisticated partners and the broader scientific/investor community.

High-touch, strategic management of large pharma collaborations (BMS)

The relationship with Bristol Myers Squibb (BMS) is definitely a cornerstone of the partnership strategy. This is a high-touch management exercise because the deliverables are complex, involving gene-edited T-cell therapies. The depth of this relationship is shown by the sheer volume of programs involved.

Here's a quick look at the scale of the Bristol Myers Squibb relationship as of late 2025:

Collaboration Metric	Value/Status
Programs Opted Into (Total)	13
Gene Targets Covered	11
Programs in IND-Enabling Studies (Q2 2025)	2
Programs in Late-Stage Discovery (Q2 2025)	4
IND/CTA Acceptance (CD19 HD Allo CAR T)	Triggered Milestone Payment in Q2 2025
Collaboration Extension End Date	2026 (with options extending into 2028)

That first IND/CTA acceptance for the CD19 HD Allo CAR T program in Q2 2025 triggered a milestone payment, showing direct financial validation from the partner. Also, revenue recognition related to a milestone achieved under the BMS collaboration was reported in the third quarter of 2025.

Direct communication with investors via press releases and SEC filings

For investors, Editas Medicine, Inc. relies on structured, scheduled disclosures, having moved away from hosting quarterly conference calls. You get your primary updates through official filings and press releases.

Key communication touchpoints in 2025 included:

• Announcing Q3 2025 results on November 10, 2025, via press release and SEC filings.
• Reporting Q1 2025 results on May 12, 2025, through press release and SEC filings.
• The company's cash position as of September 30, 2025, stood at $165.6 million.
• The projected operational cash runway extends into the third quarter of 2027.
• SEC filings in 2025 included a 10-Q on Nov 10 and an 8-K on Oct 9.

The company is defintely using these formal channels to manage expectations about its financial health and pipeline progression.

Scientific engagement through conference presentations and publications

Scientific credibility is a critical relationship builder in this sector, proving the technology works outside the lab. Editas Medicine, Inc. actively engages the scientific community by presenting data at major industry meetings.

Recent scientific engagement included:

• Presenting preclinical data for EDIT-401 at the 32nd Annual European Society of Gene and Cell Therapy (ESGCT) Congress in October/November 2025.
• Presenting EDIT-401 data at the American Heart Association (AHA) Scientific Sessions 2025.
• Sharing in vivo preclinical data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting in May 2025.
• Presenting data at the TIDES USA 2025 conference in May 2025.
• Sharing new in vivo data in June 2025 at the European Hematology Association (EHA) 2025 Congress.

Looking ahead, management planned to participate in the 8th Annual Evercore Healthcare Conference on December 2, 2025, keeping the dialogue open with the investment community.

Finance: draft 13-week cash view by Friday.

Editas Medicine, Inc. (EDIT) - Canvas Business Model: Channels

You're looking at how Editas Medicine, Inc. gets its science and corporate story out to the world, from potential pharma partners to the investors watching the ticker. It's a mix of formal scientific exchange and required financial disclosure.

Direct licensing and collaboration agreements with pharmaceutical partners

The channel for deep, long-term value creation is through these partnerships. Revenue recognition here is lumpy, tied to specific milestones being hit. For the three months ended September 30, 2025, Collaboration and other research and development revenues hit $7.5 million, a big jump from just $0.1 million for the same period in 2024. This Q3 2025 revenue spike was mainly due to a milestone achieved under the collaboration agreement with BMS.

The company's technology licensing is also a key channel, particularly the foundational IP. Editas Medicine is the exclusive licensee of Broad Institute's Cas12a patent estate and Broad Institute and Harvard University's Cas9 patent estates for human medicines. Monetizing this IP is active; for instance, Editas Medicine received an upfront cash payment of $57 million from DRI Healthcare Trust by selling certain future license fees related to the Vertex Pharmaceuticals Cas9 agreement. Those future fees range from $5 million to $40 million annually, plus a mid-double-digit percentage of a $50 million contingent upfront payment from Vertex.

Financial Metric/Agreement Detail	Value/Status as of Late 2025
Q3 2025 Collaboration Revenue	$7.5 million
Q3 2024 Collaboration Revenue	$0.1 million
Key Collaboration Partner Triggering Q3 2025 Revenue	BMS (Milestone achieved)
Upfront Payment from DRI for Vertex Fees Monetization	$57 million
Expected Annual License Fees from Vertex (Range)	$5 million to $40 million
Cash, Cash Equivalents, and Marketable Securities (Sep 30, 2025)	$165.6 million
Expected Cash Runway	Into the third quarter of 2027

Scientific conferences (ASGCT, AHA, ESGCT) for data dissemination

Disseminating preclinical data at major scientific venues validates the science. Editas Medicine presented preclinical data on its lead candidate, EDIT-401, at several key meetings in late 2025. The oral presentation at the 32nd Annual European Society of Gene and Cell Therapy (ESGCT) Congress (October 7-10, 2025) was led by the Executive Vice President and Chief Scientific Officer, Dr. Linda Burkly. The abstract number for that oral presentation was OR069.

Also, the company presented a moderated digital poster at the American Heart Association (AHA) Scientific Sessions 2025 (November 7-10, 2025). The data presented at both AHA and ESGCT demonstrated over 90% LDL-C reduction in non-human primates with EDIT-401. Earlier in the year, data was presented at the ASGCT annual meeting in May 2025.

Management also used investor conferences as a channel:

• H.C. Wainwright Genetic Medicines Virtual Conference: Fireside Chat on October 14, 2025.
• Chardan 9th Annual Genetic Medicines Conference: Panel Discussion on October 21, 2025.
• 8th Annual Evercore Healthcare Conference: Fireside Chat on December 2, 2025, at 9:10 AM EST.

Regulatory submissions (IND/CTA) to the FDA and other agencies

The path to the clinic is formalized through regulatory filings. Editas Medicine remains on track to submit an Investigational New Drug (IND) or Clinical Trial Application (CTA) for EDIT-401 by mid-2026. The goal is to achieve initial in vivo human proof-of-concept data by year-end 2026.

A key regulatory milestone was already achieved via a partner channel: the first IND/CTA was accepted for the CD19 HD Allo CAR T program, which is part of the collaboration with Bristol Myers Squibb. This acceptance triggered a milestone payment. The company also anticipated establishing one additional target cell type/tissue beyond HSCs and the liver by the end of 2025.

Investor Relations website for corporate and financial updates

The Investor Relations section of www.editasmedicine.com is the primary hub for financial transparency. The company announced its Third Quarter 2025 Results and Business Updates on November 10, 2025, via press release and SEC filings. Importantly, the company stated it does not plan to host quarterly financial results conference calls moving forward.

For public market data as of December 4, 2025, 3:50 PM EST:

Stock Metric	Value
NASDAQ Ticker	EDIT
Closing Price	$2.44
Volume	1,293,645
52 Week High	$4.54
52 Week Low	$0.91
Common Shares Outstanding (Oct 31, 2025)	97,618,660

Webcasts for investor presentations are available live, with archived replays remaining accessible for approximately 30 days following each event.

Editas Medicine, Inc. (EDIT) - Canvas Business Model: Customer Segments

You're looking at the customer base for Editas Medicine, Inc. (EDIT) as of late 2025. This is a company deep in the R&D phase, so the 'customers' aren't buying pills yet; they are partners, patients waiting for breakthroughs, and the capital markets funding the journey. Honestly, the segments reflect this high-risk, high-reward biotech reality.

Large pharmaceutical and biotech companies seeking gene editing assets

This segment is crucial because, right now, their revenue is driven by strategic alliances, not product sales. These larger entities provide the capital and potential commercial scale that Editas Medicine, Inc. needs to advance its pipeline. You can see this dependency clearly in the Q3 2025 results, where Collaboration and other research and development revenues hit $7.5 million, a massive jump from the $0.1 million in the same period in 2024. That surge was tied to a milestone achieved under the collaboration agreement with Bristol Myers Squibb (BMS). Also, the company retains rights under a license agreement with Vertex Pharmaceuticals, which contributes to their extended cash runway. These companies are buying access to Editas Medicine, Inc.'s proprietary CRISPR/Cas12a and Cas9 patent estates for human medicines.

Patients with serious genetic diseases with high unmet need (e.g., high LDL-C)

For patients, the value proposition is a potential one-time, transformative therapy. The lead in vivo development candidate, EDIT-401, targets the reduction of LDL cholesterol (LDL-C). The preclinical data is compelling: it showed a mean LDL-C reduction of >90% in non-human primates, which is significantly better than the 40%-60% mean reduction seen with standard of care therapies. The near-term action for this segment is waiting; Editas Medicine, Inc. is on track to submit the Investigational New Drug (IND) or Clinical Trial Application (CTA) for EDIT-401 by mid-2026, aiming for initial human proof-of-concept data by year-end 2026.

Here's a quick look at the pipeline progress and financial backing supporting this patient focus:

Metric	Value / Date	Relevance
EDIT-401 NHP Efficacy	>90% mean LDL-C reduction	Potential superiority over standard of care (40%-60% reduction)
Cash Runway End Date	Third quarter of 2027	Funds operations through key data milestones
Cash, Cash Equivalents, Marketable Securities (as of 9/30/2025)	$165.6 million	Financial stability for R&D progression
Target IND/CTA Submission for EDIT-401	Mid-2026	Timeline to initiate human trials

Clinical investigators and research hospitals for trials

This group is essential for executing the clinical strategy, especially as Editas Medicine, Inc. pivots to in vivo therapies targeting the liver and hematopoietic stem cells (HSCs). While specific numbers of active trial sites aren't public, their engagement is evidenced by the scientific dissemination activities. For instance, preclinical data for EDIT-401 was presented at the American Heart Association (AHA) Scientific Sessions 2025 and the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress. These presentations are how Editas Medicine, Inc. establishes credibility with the investigators who will eventually run their trials.

Institutional and individual investors in the biotech sector

Investors are buying into the potential of the CRISPR technology and the extended financial runway. As of October 31, 2025, the stock price was $3.08, with a market capitalization of $277M based on 97.6M shares outstanding. The ownership structure shows significant institutional interest; there are 327 institutional owners on file. For example, BlackRock, Inc. held 8,019,891 shares as of September 30, 2025. The market is clearly watching the burn rate; the net loss for Q3 2025 was $25.1 million, though this was narrower than the prior year's loss of $62.1 million. The company is actively managing capital, having raised $17.8 million in gross equity proceeds from its ATM facility during Q3 2025.

Investor sentiment is shaped by key financial and operational milestones:

• Stock price on December 3, 2025: $2.36
• Estimated total revenue for the full 2025 fiscal year: $12.67 million
• Number of institutional investors holding positions: 327
• Total Value of Holdings by major institutions (as of 9/30/2025): $105 million
• Net Loss for Q3 2025: $25.1 million

Editas Medicine, Inc. (EDIT) - Canvas Business Model: Cost Structure

You're looking at the major drains on Editas Medicine, Inc.'s cash reserves as they push their in vivo pipeline forward. For a company like Editas Medicine, the Cost Structure is almost entirely driven by the science.

Dominantly Research and Development (R&D) expenses are the single largest cost component. This covers everything from lab work and discovery to preclinical studies and manufacturing scale-up for their gene editing candidates. The focus has clearly shifted following the discontinuation of the reni-cel program.

The R&D spend shows a significant reduction compared to the prior year, reflecting that strategic pivot. For the third quarter ending September 30, 2025, Research and Development expenses were reported at $19.8 million. That's a sharp drop when you compare it to the $47.6 million incurred in the third quarter of 2024. To give you a broader view of the year-to-date trend, the first quarter of 2025 saw R&D expenses of $26.6 million, down from $48.8 million in Q1 2024.

The cost structure was heavily impacted by one-time charges early in the year. The first quarter of 2025 included significant restructuring and impairment charges totaling $40.9 million. These charges were tied directly to the discontinuation of the reni-cel program, covering workforce reductions and impairment of related equipment. For the nine months ended September 30, 2025, the cumulative restructuring and impairment charges amounted to $66.9 million. To be fair, Editas Medicine did not recognize any restructuring and impairment charges in the third quarter of 2025 itself.

Here's a quick look at the operating expense shift:

• Q3 2025 R&D: $19.8 million
• Q3 2024 R&D: $47.6 million
• Q3 2025 G&A: $12.3 million
• Q3 2024 G&A: $18.1 million

General and administrative costs, which cover corporate overhead, executive salaries, and non-R&D related support functions, also saw a reduction as headcount was streamlined. General and administrative expenses for Q3 2025 were $12.3 million, down from $18.1 million in Q3 2024. This reflects the reduced workforce following the December 2024 program discontinuation.

The final major cost category involves Intellectual property maintenance and licensing fees. Editas Medicine is the exclusive licensee for key CRISPR patent estates from the Broad Institute and Harvard University for human medicines. This means they incur ongoing costs to maintain these licenses, including potential milestone payments, success fees, royalty fees, and patent maintenance costs owed to licensors. While the exact recurring expense for these fees in 2025 isn't itemized separately in the high-level releases, these obligations are contingent upon future development and regulatory success.

You can see the material impact of the strategic shift on operating expenses in this comparison:

Expense Category	Period	Amount (USD)
Restructuring and Impairment Charges	Q1 2025 (Three Months)	$40.9 million
Restructuring and Impairment Charges	Nine Months Ended Sept 30, 2025 (YTD)	$66.9 million
Research and Development Expenses	Q3 2025 (Three Months)	$19.8 million
General and Administrative Expenses	Q3 2025 (Three Months)	$12.3 million

Finance: draft 13-week cash view by Friday.

Editas Medicine, Inc. (EDIT) - Canvas Business Model: Revenue Streams

You're looking at how Editas Medicine, Inc. funds its operations right now, and honestly, it's all about partnerships and hitting specific targets. For a company deep in the R&D phase, revenue isn't coming from selling a commercial product; it's coming from the value embedded in its intellectual property and the success of its collaborators.

The primary source of top-line income is clearly tied to external agreements. For the third quarter ending September 30, 2025, Collaboration and other R&D revenues hit $7.54 million. That number is a huge jump compared to the $0.1 million recognized in the same period of 2024, showing the lumpy, milestone-driven nature of this income.

Here's a quick look at how that Q3 revenue stacks up against the analyst view for the full year:

Metric	Amount
Q3 2025 Collaboration & R&D Revenue	$7.54 million
Analyst-Estimated Full-Year 2025 Revenue	$12.67 million
Q3 2024 Collaboration & R&D Revenue	$0.1 million

What this estimate hides is that the full-year number relies heavily on hitting future milestones, which is standard for this sector. If onboarding takes longer than expected, that full-year projection could shift.

The key drivers for these revenue events are structured around the value of Editas Medicine's gene editing platform:

• Collaboration and other R&D revenues (Q3 2025: $7.54 million).
• Milestone payments from strategic partners, such as the recognition tied to the Bristol Myers Squibb (BMS) collaboration, specifically following an Investigational New Drug (IND) application acceptance for their CD19 HD Allo CAR T program.
• Licensing and sublicensing revenue from foundational CRISPR IP, evidenced by retained payments under the license agreement with Vertex Pharmaceuticals, which contributes to extending the cash runway.

To be fair, the Q3 surge was almost entirely due to one significant event. The increase was primarily attributable to the recognition of revenue related to a milestone achieved under the Company's collaboration agreement with BMS in the third quarter of 2025. This underscores that revenue visibility is low until a specific development or regulatory event occurs.

Finance: draft 13-week cash view by Friday.